Skip to main content
SpringerLink
Log in

The Clinical Implications of Inhibition of the Inducible Form of Cyclo-Oxygenase

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Summary

There are 2 isoenzymes of cyclo-oxygenase (COX). There is a constitutive enzyme COX-1 which has a wide tissue distribution. In addition there is an inducible enzyme COX-2 which has a restricted tissue distribution. The inducible enzyme COX-2 is responsible for the generation of prostaglandins at sites of tissue inflammation and its inhibition is associated with an anti-inflammatory action. The constitutive enzyme, COX-1 is responsible for the production of prostaglandins with multiple functions. One well known and clinically important function is the gastroprotective effect of the prostaglandins produced in the gastric mucosa. While selective COX-2 inhibition may be associated with a reduced incidence of gastric adverse effects, a concern remains that its inhibition at other locations may be associated with other adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin like drugs. Nature 1971; 231: 235–7

    Google Scholar 

  2. Smith WL, Borgeat P, Fitzpatrick FA. The eicosanoids: cyclooxygenase, lipooxygenase, and epoxygenase pathways. In: Vance DE, Vance J, editors. Biochemistry of lipids, lipoproteins and membranes. Oxford: Elsevier Science Publishers, 1991: 297–325

    Google Scholar 

  3. Solomon LM, Juhlin L, Kirchenbain MB. Prostaglandins on cutaneous vasculature. J Invest Dermatol 1968; 51: 280–2

    PubMed  CAS  Google Scholar 

  4. Ferreira SH. Prostaglandins, aspirin like drugs and analgesia. Nature 1992; 240: 200–3

    Google Scholar 

  5. Appleton I, Tomlinson A, Mitchell JA, et al. Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation. Implications for future anti-inflammatory therapy. J Pathol 1995; 176(4): 413–20

    Article  PubMed  CAS  Google Scholar 

  6. Dunn MJ. Non steroidal anti inflammatory drugs and renal function. Annu Rev Med 1984; 35: 411–28

    Article  PubMed  CAS  Google Scholar 

  7. Miller TA. Protective effects of prostaglandins against mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983; 245: G601–23

    PubMed  CAS  Google Scholar 

  8. Bunting S, Moncada S, Vane JR. The prostacyclin-thromboxane balance: pathophysiological and therapeutic considerations. Br Med Bull 1983; 39: 271–6

    PubMed  CAS  Google Scholar 

  9. O’Banion MK, Sadowski HB, Winn V, et al. A serum and glucocorticoid regulated 4-kilobase mRNA encodes a cyclooxygenase related protein. J Biol Chem 1991; 266: 23261–7

    PubMed  Google Scholar 

  10. Kujubu DA, Herschman HR. Dexamethasone inhibits nitrogen induction of the TIS10 prostaglandin synthase/cyclo-oxygenase gene. J Biol Chem 1992; 267: 7991–4

    PubMed  CAS  Google Scholar 

  11. Sirois J, Richards JS. Purification and characterisation of a novel, distinct isoform of prostaglandin enderoperoxide synthase induced by human chorionic gonadotrophin in granulosa cells of rat pre ovulatory follicles. J Biol Chem 1992; 267: 6382–8

    PubMed  CAS  Google Scholar 

  12. Appleton I, Tomlinson A, Willoughby DA. Inducible cyclo-oxygenase (COX2): a safer therapeutic target? Br J Rheumatol 1995;33(5): 410–2

    Article  Google Scholar 

  13. Mead EA, Smith WL, De Witt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non steroidal anti inflammatory drugs. J Biol Chem 1992; 268: 6610–4

    Google Scholar 

  14. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692–6

    Article  PubMed  CAS  Google Scholar 

  15. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase 1 and 2 expression in rheumatoid synovial tissues: effect of interleukin 1β, Phorbol esters, and corticosteroids. J Clin Invest 1994; 93: 1095–101

    Article  PubMed  CAS  Google Scholar 

  16. Knott I, Dieu M, Burton M, et al. Induction of cyclooxygenase by interleukin 1: comparative study between human synovial cells and chondrocytes. J Rheumatol 1994; 21: 462–6

    PubMed  CAS  Google Scholar 

  17. Schoen RT, Vender RJ. Mechanism of nonsteroidal anti-inflammatory drug induced gastric damage. Am J Med 1989; 86: 449–57

    Article  PubMed  CAS  Google Scholar 

  18. Blanco A, Habib A, Levy-Toledano S, et al. Involvement of tyrosine kinases in the induction of cyclooxygenase-2 in human endothelial cells. Biochem J 1995; 312 (Pt 2): 419–23

    PubMed  CAS  Google Scholar 

  19. Inoue H, Yokoyama C, Hara S, et al. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells.Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995; 270(42): 249675–1

    Article  Google Scholar 

  20. Rimarachin JA, Jacobson JA, Szabo P, et al. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 1994; 14(7): 1021–31

    Article  PubMed  CAS  Google Scholar 

  21. Akai Y, Homma T, Burns KD, et al. Mechanical stretch/relaxation of cultured rat mesangial cells induces protooncogenes and cyclooxygenase. Am J Physiol 1994; 267: C482–90

    PubMed  CAS  Google Scholar 

  22. Martin M, Neumann D, Hoff T, et al. Interleukin-1 induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 1994; 45: 150–8

    Article  PubMed  CAS  Google Scholar 

  23. Yamagata K, Andreasson KI, Kauffman WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11(2): 371–86

    Article  PubMed  CAS  Google Scholar 

  24. Adams, Cillaco-Morase Y, De Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 1996; 66(1): 6–13

    Article  PubMed  CAS  Google Scholar 

  25. Vanderburgh HH, Shansky J, Solerssi R, et al. Mechanical stimulation of skeletal muscle increases prostaglandin F2 alpha production, cyclooxygenase activity, and cell growth by a pertussin toxin sensitive mechanism. J Cell Physiol 1995; 163(2): 285–94

    Article  Google Scholar 

  26. Jacobs AL, Hwang D, Julian J, et al. Regulated expression of prostaglandin endoperoxide synthase-2 by uterine stroma. Endocrinology 1994; 135: 1807–15

    Article  PubMed  CAS  Google Scholar 

  27. Slater DM, Berger LC, Newton, et al. Expression of cyclooxygenase types 1 and 2 in human fetal membranes at term. Am J Obstet Gynaecol; 172 (1 Pt 1): 77–82

  28. Englehardt G. Meloxicam: a potent inhibitor of COX2 [abstract]. 9th International Conference on Prostaglandins and Related Compounds: 1994 Jun 6–10; Florence: 82

  29. Meade EA, Smith WL, De Witt DL. Differential inhibition of prostaglandin enderoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268(9): 6610–4

    PubMed  CAS  Google Scholar 

  30. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible COX 1. Proc Natl Acad Sci USA 1994; 90: 11163–697

    Google Scholar 

  31. Barnett J, Chow J, Ives D, et al. Purification, characterisation and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994; 1209(1): 130–9

    Article  PubMed  CAS  Google Scholar 

  32. Langman MJS, Weil J. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8

    Article  PubMed  CAS  Google Scholar 

  33. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994; 343: 769–72

    Article  PubMed  CAS  Google Scholar 

  34. Singh G, Ramey DR, Morfeld D, et al. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther 1994; 62: 175–91

    Article  PubMed  CAS  Google Scholar 

  35. Fries JF, Spitz PW, Williams CA, et al. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990; 34: 121–30

    Article  Google Scholar 

  36. Richardson CE, Emery P. Innovative treatment approaches for rheumatoid arthritis. Baillieres Clin Rheumatol 1995; 9(4): 731–58

    Article  PubMed  CAS  Google Scholar 

  37. Blower PR. The unique pharmacological profile of nabumetone. J Rheumatol 1992; 19 Suppl. 36: 13–9

    Google Scholar 

  38. Gerson GC. Worldwide safety experience with nabumetone. J Rheumatol 1992; 19 Suppl. 36: 48–56

    Google Scholar 

  39. Wilkens RF. An overview of the long term safety experience of nabumetone. Drugs 1990; 40 Suppl. 5: 34–7

    Article  Google Scholar 

  40. Fleishman RM. Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. J Rheumatol 1992; 19 Suppl. 36: 32–40

    Google Scholar 

  41. Jackson RE, Mitchell FN, Brindley DA. Safety evaluation of nabumetone in US clinical trials. Am J Med 1987; 83 Suppl. 4B: 115–20

    Article  PubMed  CAS  Google Scholar 

  42. Jenner PM, Johnson ES. Review of experience with nabumetone in clinical trials outside of the United States. Am J Med 1987; 83 Suppl. 4B: 110–4

    Article  PubMed  CAS  Google Scholar 

  43. Inman WHW, Wilton WV, Pearce GI, et al. Prescription event monitoring with nabumetone. Pharm Med 1990; 4: 309–17

    Google Scholar 

  44. Hochberg MC. Association of non steroidal anti-inflammatory drugs with upper gastrointestinal disease: epidemiological and economic considerations. J Rheumatol 1992; 19 Suppl. 36: 63–7

    Google Scholar 

  45. Soll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322: 909–16

    Article  PubMed  CAS  Google Scholar 

  46. Arnoff GR. Therapeutic implications associated with renal studies of nabumetone. J Rheumatol 1992; 19 Suppl. 36: 25–31

    Google Scholar 

  47. Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm 1990; 10: 56–65

    PubMed  CAS  Google Scholar 

  48. Tana AS, McLaughlin S, Holland PJ, et al. Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis. Ann Rheum Dis 1990; 49: 354–8

    Article  Google Scholar 

  49. Lee DKH. Effect of etodolac on the prostaglandin concentration in the kidney of the normal rat. Drug Dev Res 1986; 9(4): 305–11

    Article  CAS  Google Scholar 

  50. Glaser K, Sung ML, O’Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHs-2) versus PGHS 1. Eur J Pharmacol 1995; 281: 107–11

    Article  PubMed  CAS  Google Scholar 

  51. Turck D, Roth W, Busch U. A review of the pharmacokinetics of meloxicam. Br J Rheumatol 1996; 35 Suppl.: 13–6

    Article  PubMed  Google Scholar 

  52. Degner F, Heinzel G, Busch U. Transsynovial kinetics of meloxicam [abstract]. Scand J Rheumatol 1994; Suppl. 98: 121

  53. Busch U, Englehart G. Distribution of [14C] meloxicam in joints of rats with adjuvant arthritis. Drugs Exp Clin Res 1990: 16; 49–52

    PubMed  CAS  Google Scholar 

  54. Englehart JG, Bogel R, Schnitzler C, et al. Meloxicam: influence on arachidonic acid metabolism. Part II. In vitro findings. Biochem Pharmacol 1996; 51(1): 29–38

    Article  Google Scholar 

  55. Distel M, Mueller C, Bluhmki E, et al. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996: 35 Suppl. 1; 68–77

    Article  PubMed  CAS  Google Scholar 

  56. Linden B, Distel M, Bluhmki E. A double blind study to compare the efficacy and safety of meloxicam 15mg with piroxicam 20mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996; 35 Suppl. 1: 35–8

    Article  PubMed  CAS  Google Scholar 

  57. Hosie J, Distel M, Blumhki E. Meloxicam in osteoarthritis: a 6 month double blind comparison with diclofenac sodium. Br J Rheumatol 1996; 35 Suppl. 1: 39–43

    Article  PubMed  CAS  Google Scholar 

  58. Wojtulewski JA, Schattenkirchner M, Barcelo P, et al. A six month double blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily patients with rheumatoid arthritis. Br J Rheumatol 1996; 35 Suppl. 1: 22–9

    Article  PubMed  CAS  Google Scholar 

  59. Huskisson EC, Narjes H, Bluhmki E. Efficacy and tolerance of meloxicam, a new NSAID in daily oral doses of 15, 30 and 60mg in comparison with 20mg piroxicam in patients with rheumatoid arthritis [abstract]. Scand J Rheumatol 1994: Suppl. 98: 115

  60. Huskisson EC, Ghozian R, Kurthen R, et al. A long term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35 Suppl. 1: 29–34

    Article  PubMed  CAS  Google Scholar 

  61. Dinchuck JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378; 406–9

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology and Rehabilitation, University of Leeds, 36 Clarendon Road, Leeds, LS2 9NZ, England

    Charles Richardson & Paul Emery

Authors
  1. Charles Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Emery
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richardson, C., Emery, P. The Clinical Implications of Inhibition of the Inducible Form of Cyclo-Oxygenase. Drug-Safety 15, 249–260 (1996). https://doi.org/10.2165/00002018-199615040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199615040-00003

Keywords

Search

Navigation